Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the USA / NCT07567365
Starting soon Not applicable

Clinical Outcomes of Focused Shockwave Therapy Without Adjunct Rehabilitation Compared to Standard Physical Rehabilitation in Patients With Grade I-III Knee Osteoarthritis: A Single-Blind Randomized Study

NCT07567365 · tracked via the Priya Life Science USA tracker
Sponsor
Pulse Wave USA
Phase
Not applicable
Started
2027-09-25
Last updated
2026-05-05

Condition(s) studied

Knee Osteoarthristis

Investigational drug(s) / intervention(s)

Physical RehabFocused Shockwave Therapy

Physical Rehab: Physical rehab through the use of body weight exercises, resistance bands, weights, movement, repetitive movement.

Focused Shockwave Therapy: Applying focused shockwave therapy using a focused shockwave therapy device to the treatment area.

Study summary

Clinical Outcomes of Focused Shockwave Therapy Without Adjunct Rehabilitation Compared to Standard Physical Rehabilitation in Patients with Grade I-III Knee Osteoarthritis: A Single-Blind Randomized Study

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patient must have diagnosed OA of the unilateral or bilateral knee(s) sufficient to qualify as grade I, II, or III O.A. Exclusion Criteria: * Patients without diagnosable or gradable O.A. of the knee or knees.

Primary outcome measure(s)

  • Change in WOMAC Pain Subscale score from baseline to the primary endpoint - likely 8 or 12 weeks after treatment begins. — 8 to 12 weeks
    The primary outcome measure will be the between-group difference in change from baseline in WOMAC Pain Subscale score at 12 weeks.

Trial sites (1)

FacilityCityRegionStatus
Westminster Spine & Injury Center Westminster Colorado

Other trials for the same condition

geniculaR Artery eMBolization for Knee Osteoarthritis (RAMBO) Registry Recruiting
Prospective, In-Vivo, Post-Market Safety and Efficacy Surveillance Registry of the MAXX Orthopedics, Freedom Total Knee® System Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07567365 on ClinicalTrials.gov ↗ ← All trials in the USA